<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">34459327</PMID><DateCompleted><Year>2022</Year><Month>05</Month><Day>05</Day></DateCompleted><DateRevised><Year>2022</Year><Month>06</Month><Day>08</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2167-9223</ISSN><JournalIssue CitedMedium="Internet"><Volume>23</Volume><Issue>3-4</Issue><PubDate><Year>2022</Year><Month>May</Month></PubDate></JournalIssue><Title>Amyotrophic lateral sclerosis &amp; frontotemporal degeneration</Title><ISOAbbreviation>Amyotroph Lateral Scler Frontotemporal Degener</ISOAbbreviation></Journal><ArticleTitle>Clinical management and disease-modifying treatment for amyotrophic lateral sclerosis in African hospital centers: the TROPALS study.</ArticleTitle><Pagination><StartPage>279</StartPage><EndPage>283</EndPage><MedlinePgn>279-283</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1080/21678421.2021.1961806</ELocationID><Abstract><AbstractText><i>Objective:</i> To assess the availability of health workers and medications for clinical management of amyotrophic lateral sclerosis (ALS) in African hospital centers. Availability and affordability analyses of disease-modifying treatments were performed. <i>Methods</i>: A multicenter observational study involving African hospitals was conducted. A standard questionnaire was developed based on the European Federation of the Neurological Societies (EFNS) guidelines. We collected data on multidisciplinary care and availability of medicines. The availability and affordability were evaluated according to the WHO guidelines. <i>Results</i>: Nine hospital centers from eight African countries participated. We observed a low degree of implementation of multidisciplinary care in ALS management. Riluzole was only available in centers from South Africa, Senegal, Tunisia, and Togo. This treatment was unaffordable and the adjusted price was highly variable among countries. The cost of riluzole was partly or fully covered by patients, which implies a substantial economic burden. <i>Conclusion</i>: Our findings strengthen the need to promote multidisciplinary care in the clinical management of ALS in Africa. Disease-modifying medication should be both available and affordable. Local and international collaboration is needed to improve ALS health care access in Africa.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Luna</LastName><ForeName>Jaime</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-5990-7534</Identifier><AffiliationInfo><Affiliation>INSERM, Univ. Limoges, CHU Limoges, IRD, U1094 Tropical Neuroepidemiology, Institute of Epidemiology and Tropical Neurology, GEIST, Limoges, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, CHU Limoges, Centre de R&#xe9;f&#xe9;rence SLA et autres maladies du neurone moteur, Limoges, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jost</LastName><ForeName>Jeremy</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>INSERM, Univ. Limoges, CHU Limoges, IRD, U1094 Tropical Neuroepidemiology, Institute of Epidemiology and Tropical Neurology, GEIST, Limoges, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Diagana</LastName><ForeName>Mouhamadou</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>INSERM, Univ. Limoges, CHU Limoges, IRD, U1094 Tropical Neuroepidemiology, Institute of Epidemiology and Tropical Neurology, GEIST, Limoges, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neurology Department, CHU de Nouakchott, Mauritania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ait Aissa</LastName><ForeName>Leila</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Laboratoire de Recherche en Neurosciences Universit&#xe9; Benyoucef Benkhedda, Alger 1, Service de Neurologie CHU Mustapha, Alg&#xe9;rie.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tazir</LastName><ForeName>Meriem</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Laboratoire de Recherche en Neurosciences Universit&#xe9; Benyoucef Benkhedda, Alger 1, Service de Neurologie CHU Mustapha, Alg&#xe9;rie.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ali Pacha</LastName><ForeName>Lamia</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Laboratoire de Recherche en Neurosciences Universit&#xe9; Benyoucef Benkhedda, Alger 1, Service de Neurologie CHU Mustapha, Alg&#xe9;rie.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kacem</LastName><ForeName>Imen</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Neurology, LR18SP03, Clinical Investigation Center of Neurosciences and Mental Health , Universitary Hospital Razi-Mannouba, Tunis, Tunisia, Faculty of Medicine of Tunis, University of Tunis El Manar, Tunis, Tunisia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gouider</LastName><ForeName>Riadh</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Neurology, LR18SP03, Clinical Investigation Center of Neurosciences and Mental Health , Universitary Hospital Razi-Mannouba, Tunis, Tunisia, Faculty of Medicine of Tunis, University of Tunis El Manar, Tunis, Tunisia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Henning</LastName><ForeName>Franclo</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0002-4006-8101</Identifier><AffiliationInfo><Affiliation>Division of Neurology, Department of Medicine, Faculty of Medicine and Health Sciences, Stellenbosch University, South Africa.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Basse</LastName><ForeName>Anna</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Neurology Department, CHNU Fann, UCAD, Dakar, Senegal.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cisse</LastName><ForeName>Ousmane</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Neurology Department, CHNU Fann, UCAD, Dakar, Senegal.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Balogou</LastName><ForeName>Aa Koffi</ForeName><Initials>AK</Initials><AffiliationInfo><Affiliation>Neurology Department, CHU Campus Universit&#xe9; de Lom&#xe9;.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kombate</LastName><ForeName>Damelan</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Neurology Department, CHU Campus Universit&#xe9; de Lom&#xe9;.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Agbetou</LastName><ForeName>Mendinatou</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Faculty of Health Sciences, Laboratory of Chronic and Neurologic Diseases Epidemiology, University of Abomey-Calavi, Cotonou, B&#xe9;nin; Neurology Unit, CNHU Cotonou, Cotonou, B&#xe9;nin.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Houinato</LastName><ForeName>Dismand</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>INSERM, Univ. Limoges, CHU Limoges, IRD, U1094 Tropical Neuroepidemiology, Institute of Epidemiology and Tropical Neurology, GEIST, Limoges, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculty of Health Sciences, Laboratory of Chronic and Neurologic Diseases Epidemiology, University of Abomey-Calavi, Cotonou, B&#xe9;nin; Neurology Unit, CNHU Cotonou, Cotonou, B&#xe9;nin.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gnonlonfoun</LastName><ForeName>Dieu Donn&#xe9;</ForeName><Initials>DD</Initials><AffiliationInfo><Affiliation>Faculty of Health Sciences, Laboratory of Chronic and Neurologic Diseases Epidemiology, University of Abomey-Calavi, Cotonou, B&#xe9;nin; Neurology Unit, CNHU Cotonou, Cotonou, B&#xe9;nin.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Millogo</LastName><ForeName>Athanase</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>INSERM, Univ. Limoges, CHU Limoges, IRD, U1094 Tropical Neuroepidemiology, Institute of Epidemiology and Tropical Neurology, GEIST, Limoges, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neurology Department, CHU Sour&#xf4; Sanou, Bobo-Dioulasso, Universit&#xe9; Joseph Ki- Zerbo Burkina Faso, and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Agba</LastName><ForeName>Thierry</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Universit&#xe9; de Lom&#xe9;, Togo.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Belo</LastName><ForeName>Mouftao</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Universit&#xe9; de Lom&#xe9;, Togo.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sengxeu</LastName><ForeName>Noudy</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>INSERM, Univ. Limoges, CHU Limoges, IRD, U1094 Tropical Neuroepidemiology, Institute of Epidemiology and Tropical Neurology, GEIST, Limoges, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hamidou</LastName><ForeName>Bello</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>INSERM, Univ. Limoges, CHU Limoges, IRD, U1094 Tropical Neuroepidemiology, Institute of Epidemiology and Tropical Neurology, GEIST, Limoges, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Preux</LastName><ForeName>Pierre-Marie</ForeName><Initials>PM</Initials><Identifier Source="ORCID">0000-0002-2171-2977</Identifier><AffiliationInfo><Affiliation>INSERM, Univ. Limoges, CHU Limoges, IRD, U1094 Tropical Neuroepidemiology, Institute of Epidemiology and Tropical Neurology, GEIST, Limoges, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Benoit</LastName><ForeName>Marin</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>INSERM, Univ. Limoges, CHU Limoges, IRD, U1094 Tropical Neuroepidemiology, Institute of Epidemiology and Tropical Neurology, GEIST, Limoges, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Couratier</LastName><ForeName>Philippe</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>INSERM, Univ. Limoges, CHU Limoges, IRD, U1094 Tropical Neuroepidemiology, Institute of Epidemiology and Tropical Neurology, GEIST, Limoges, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, CHU Limoges, Centre de R&#xe9;f&#xe9;rence SLA et autres maladies du neurone moteur, Limoges, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>Tropals Collaboration</CollectiveName></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D064888">Observational Study</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>08</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Amyotroph Lateral Scler Frontotemporal Degener</MedlineTA><NlmUniqueID>101587185</NlmUniqueID><ISSNLinking>2167-8421</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>7LJ087RS6F</RegistryNumber><NameOfSubstance UI="D019782">Riluzole</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006761" MajorTopicYN="N">Hospitals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019782" MajorTopicYN="Y">Riluzole</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Africa</Keyword><Keyword MajorTopicYN="N">Amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">affordability</Keyword><Keyword MajorTopicYN="N">availability</Keyword><Keyword MajorTopicYN="N">management</Keyword><Keyword MajorTopicYN="N">riluzole</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>8</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>5</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>8</Month><Day>30</Day><Hour>8</Hour><Minute>43</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34459327</ArticleId><ArticleId IdType="doi">10.1080/21678421.2021.1961806</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>